We are excited to inform you that Quinn Healthcare along with other sites in the US are conducting the Eli Lilly Covid-19 treatment study (Bamlanivimab). We have been conducting this study since year October 2020. The study has shown significant benefits with a quick symptom turnaround time. On March 5th, the White House purchased 10 million vials of the antibody treatment for patients who test positive for Covid-19.
The study is presently at a phase where all patients will receive the treatment drug. The placebo has been removed from the trial.
In addition to receiving the study drug at no charge, the patients will receive continuous followup for 85 days following the infusion. Also, participants will be compensated for their participation.
Children of all ages (10 Lbs. and over) and adults qualify for this potentially life-saving treatment!
For more information, contact Alicia Wilkes, FNP-C at 601-521-5551.
View this video for more information on the opportunity: